Napster cofounder Sean Parker gives cancer immunotherapy development a boost
Fueled by a $250-million commitment of funds by Napster cofounder Sean Parker, researchers from more than 40 laboratories and six of the nation’s leading cancer research centers have entered into a first-of-its-kind collaboration to accelerate the development of cancer immunotherapies.
Under the aegis of the Parker Institute for Cancer Immunotherapy, which launches Wednesday, researchers working in this once-obscure field will share their research findings, coordinate their clinical trials, establish common tissue banks and strike licensing deals with pharmaceutical companies to bring new cancer treatments to the market.
Several “checkpoint inhibitor” drugs, which release the immune system’s natural brakes so that it can attack cancers, have been approved by the Food and Drug Administration and are showing early successes in treating melanoma and cancers of the lungs and kidneys. But more than 1,500 additional cancer immunotherapy drugs are in the research-and-development pipeline, making this field the second-largest incubator of drug development.
For all the emerging evidence of its promise, Parker said in an interview Tuesday night, “this is a classic example of where the funding system around medical research was really slow to adapt” -- and where academic and commercial secrecy has impeded progress. Funded by his philanthropy and guided by a board of directors and scientific steering committee devoted to making progress in this field, Parker said that worthy research on cancer immunotherapies will no longer die for lack of funding, recognition or academic commitment.
The six academic institutions that will coordinate their efforts on immunotherapies are: Memorial Sloan Kettering Cancer Center, Stanford Medicine, UCLA, UC San Francisco, the University of Pennsylvania, and the University of Texas MD Anderson Cancer Center.
Specifically, Parker said his institute will place its initial bets on three broad areas of research: developing a new generation of T-cell therapies; investigating new uses for, and effective new combinations of, the kinds of “checkpoint inhibitor” drugs that have already proved effective for skin, lung and kidney cancers; and improving the effectiveness and potential uses for vaccines and cellular therapies in fighting a wider array of cancers.
Parker’s $250-million commitment of funds to the project is the largest philanthropic underwriting of research in this field. In an interview, Parker said he had “done a deep dive” on immunotherapy (in 2014, he donated $24 million to Stanford University Medical School for allergy research), and found the field “a good intellectual challenge.”
Parker said he was also “galvanized” by the commitment of Hollywood producer Laura Ziskin (“Pretty Woman,” “Spider-Man”), who cofounded Stand Up to Cancer and died in 2011.
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.